report-bg

Pancreatic Elastase Testing Market

Segmentation by Application (Cystic Fibrosis, Diabetes Mellitus, Chronic Pancreatitis, Pancreatic Insufficiency, and Others); and by End-User (Diagnostic Centers, Hospitals and Clinics, Pathology Laboratories, Research Centers, and Others) – Global Demand Analysis & Opportunity Outlook 2031

Buy Now
Report ID: 4043 | Published On: Feb 02, 2023
Request Free Sample Copy

Global Pancreatic Elastase Testing Market Regional Synopsis

On the basis of geographical analysis, the global pancreatic elastase testing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness modest growth over the forecast period on the back of improving healthcare infrastructure in the developing countries, along with the growing prevalence of pancreatic cancer in the region.

The market in the North America region is anticipated to gain a significant market share throughout the forecast period owing to the growing prevalence of chronic pancreatitis in the region. According to the data by the National Pancreas Foundation, the prevalence of chronic pancreatitis is 50 per 100,000 individuals in the United States, and is more common in men than women.

On the other hand, the market in Europe occupied the largest market share in 2021, owing to the presence of the advanced healthcare facilities, favorable health insurance and reimbursement policies, and high healthcare expenditure in the developed countries, such as, Germany, Switzerland, France, Sweden, Norway, and Denmark.  

Pancreatic Elastase Testing Market Share Image

Get more information on this report: Request Sample PDF

The global pancreatic elastase testing market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook


Pancreatic Elastase Testing Market Graph
Get more information on this report: Request Sample PDF

Major Macro-Economic Indicators Impacting the Market Growth

Global Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.


Market Segmentation

Our in-depth analysis of the global pancreatic elastase testing market includes the following segments:

By Application

  • Cystic Fibrosis
  • Diabetes Mellitus
  • Chronic Pancreatitis
  • Pancreatic Insufficiency
  • Others

By End-User

  • Diagnostic Centers
  • Hospitals and Clinics
  • Pathology Laboratories
  • Research Centers
  • Others

Growth Drivers

  • Increasing Prevalence of Chronic Pancreatitis
  • Rapid Advancement in the Diagnostic Technologies
  • High Global Health Expenditure

Challenges

  • Requirement of High Initial Investment
  • Lack of Researchers and Practitioners in Pathological Science 


Global Healthcare Expenditure per Capita Graph
Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Market

    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • BIOMERIEUX PLC
    • Becton, Dickinson and Company
    • Bioserv Diagnostics Gmbh
    • Novozymes A/S
    • AB Enzymes GmbH
    • Buhlmann Diagnostics Corp

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the pancreatic elastase testing market?

Ans: The increasing prevalence of chronic pancreatitis is estimated to boost the market growth.

2) What would be the CAGR of pancreatic elastase testing market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022 – 2031.

3) What are the challenges affecting the pancreatic elastase testing market growth?

Ans: The lack of researchers and practitioners in pathological science is estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of pancreatic elastase testing market in future?

Ans: The North America region is anticipated to provide more business opportunities over the forecast period owing to the growing prevalence of chronic pancreatitis in the region.

5) Who are the major players dominating the pancreatic elastase testing market?

Ans: The major players in the market are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., BIOMERIEUX PLC, Bioserv Diagnostics Gmbh, Novozymes A/S, AB Enzymes GmbH, and Buhlmann Diagnostics Corp.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the pancreatic elastase testing market?

Ans: The market is segmented by application, end-user, and by region.

8) Which segment captures the largest market size in application segment in the pancreatic elastase testing market?

Ans: The chronic pancreatitis segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample